Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Has anyone heard if we have NASDAQ approval yet? I see in the SEC filings CATS registered a couple days ago.
Catasys will be selling $15 million worth of shares which typically has a negative effect on the share price.
https://www.sec.gov/Archives/edgar/data/1136174/000143774917002126/cats20170209_s1.htm
Would you buy this tomorrow as a result of this? (Canadian noob here)
CATS one for 6 reverse split:
http://otce.finra.org/DLSymbolNameChanges
they filed an S-1 which means they're going to raise money soon
https://www.sec.gov/Archives/edgar/data/1136174/000143774917002126/cats20170209_s1.htm
News. Company growing fast. Nice to watch.
Catasys Expands OnTrak-A Solution to Massachusetts with Leading National Health Insurance Provider
LOS ANGELES, Feb. 16, 2017 /PRNewswire/ -- Catasys, Inc. (CATS), a provider of proprietary predictive analytics and integrated treatment solutions to health plans, announced today that it has entered into an agreement to expand its OnTrak™-A solution with one of the nation's leading health plans to Massachusetts. The plan's eligible commercial and Medicare Advantage members will be covered under OnTrak-A, a 52-week, multi-phase program in which enrolled members receive medical and psychosocial interventions, as well as intensive care coaching.
"We are pleased to expand our OnTrak-A solution into Massachusetts for eligible commercial and Medicare Advantage members. This represents the eighth state in which we have announced the launch of the OnTrak-A program and builds on our existing operation in Massachusetts," said Rick Anderson, Catasys' President and COO. "We look forward to improving the health and lives of our enrolled members and their families while reducing overall medical treatment costs for the health plan."
According to the U.S. Department of Health and Human Services' National Survey on Drug Use and Health: Mental Health Findings for 2013, approximately 20 million (8.5%) adults in the U.S. met criteria for a substance use disorder (i.e., illicit drug or alcohol dependence or abuse). The National Institute of Mental Health reports anxiety disorders are the most common mental illness in the U.S., affecting 18.1% of the U.S. adult population, or approximately 43 million people age 18 and older. People with an anxiety disorder are three to five times more likely to go to the doctor and six times more likely to be hospitalized for psychiatric disorders than those who do not suffer from anxiety disorders. In addition, in 2013, an estimated 15.7 million U.S. adults aged 18 or older, or 6.7% of all U.S. adults, had at least one major depressive episode in the past year based on a study conducted by the National Survey on Drug Use and Health.
Catasys' OnTrak program is designed to improve patient health while lowering costs to the insurer for underserved populations in which behavioral health conditions are exacerbating co-existing medical conditions. OnTrak has demonstrated effectiveness with a 50% reduction in health care costs for members enrolled in the program as well as reductions in hospital days, ambulance usage, emergency room visits and more thorough identification, engagement and treatment. Catasys currently operates programs in Florida, Georgia, Illinois, Kansas, Kentucky, Louisiana, Massachusetts, Missouri, New Jersey, North Carolina, Oklahoma, Pennsylvania, South Carolina, Tennessee, Texas, Virginia, West Virginia and Wisconsin.
This stock will be one of the biggest winners the next 2 years
More news out
Catasys Expands OnTrak-A Solution to Texas with Leading National Health Insurance Provider
PR Newswire
LOS ANGELES, Feb. 7, 2017
LOS ANGELES, Feb. 7, 2017 /PRNewswire/ -- Catasys, Inc. (OTCQB: CATS), a provider of proprietary predictive analytics and integrated treatment solutions to health plans, announced today that it has entered into an agreement to expand its OnTrak™-A solution with one of the nation's leading health plans to Texas. The plan's eligible commercial and Medicare Advantage members will be covered under OnTrak-A, a 52-week, multi-phase program in which enrolled members receive medical and psychosocial interventions, as well as intensive care coaching.
"We are excited to now provide our OnTrak-A solution to eligible commercial and Medicare Advantage members in Texas, which is the plan's largest state by membership. This represents the seventh state in which we have announced the launch of the OnTrak-A program. We are gratified to be adding our second largest national health plan to partner with us in the state of Texas," said Rick Anderson, Catasys' President and COO. "We are pleased with the rollout of OnTrak and the increased availability of our solution to members in Texas. We look forward to improving the health and lives of our enrolled members and their families while reducing overall medical treatment costs for the health plan."
According to the U.S. Department of Health and Human Services' National Survey on Drug Use and Health: Mental Health Findings for 2013, approximately 20 million (8.5%) adults in the U.S. met criteria for a substance use disorder (i.e., illicit drug or alcohol dependence or abuse). The National Institute of Mental Health reports anxiety disorders are the most common mental illness in the U.S., affecting 18.1% of the U.S. adult population, or approximately 43 million people age 18 and older. People with an anxiety disorder are three to five times more likely to go to the doctor and six times more likely to be hospitalized for psychiatric disorders than those who do not suffer from anxiety disorders. In addition, in 2013, an estimated 15.7 million U.S. adults aged 18 or older, or 6.7% of all U.S. adults, had at least one major depressive episode in the past year based on a study conducted by the National Survey on Drug Use and Health.
Catasys' OnTrak program is designed to improve patient health while lowering costs to the insurer for underserved populations in which behavioral health conditions are exacerbating co-existing medical conditions. OnTrak has demonstrated effectiveness with a 50% reduction in health care costs for members enrolled in the program as well as reductions in hospital days, ambulance usage, emergency room visits and more thorough identification, engagement and treatment. Catasys currently operates programs in Florida, Georgia, Illinois, Kansas, Kentucky, Louisiana, Massachusetts, Missouri, North Carolina, New Jersey, Oklahoma, Pennsylvania, South Carolina, Tennessee, Texas, Virginia, West Virginia and Wisconsin.
HUGE NEWS indeed!!!!!!
United Health is the largest HC provider in the world. On Trak-U....makes it obvious it's them
On-Trak-A (Aetna) On Trak-H (Humana)
This stock is extremely undervalued
Great news out:
Catasys Contracts with the Largest U.S. Health Insurance Company
- OnTrak-U Solution initially launching in 8 states
- OnTrak-U Solution will cover depression, anxiety, and substance use disorder
- Investor Call to be held today, February 2nd at 4:30 pm ET/ 1:30 pm PT
LOS ANGELES, Feb. 2, 2017 /PRNewswire/ -- Catasys, Inc. (OTCQB: CATS), a provider of proprietary predictive analytics and integrated treatment solutions to health plans, announced today that it has contracted with the largest national health insurance company in the United States (the "Insurer") to implement its OnTrak solution for anxiety, depression and substance use disorders (OnTrak-U). OnTrak-U is anticipated to launch in the first half of 2017 in eight states where OnTrak is already available to members of other leading health plans, with a case rate fee when members enroll plus a sharing of savings with the health plan.
Catasys eligible members average approximately $30,000 in costs to health insurers per year, and Catasys has been shown to reduce inpatient and emergency room utilization, driving an approximately 50 percent average reduction in total health insurers' costs for enrolled members from the year prior to enrollment.
This contract will leverage Catasys' proprietary analytic models to identify impactable members to engage and is anticipated to significantly contribute towards the Company's goal of Equivalent Lives covered under contract of 20 million by the end of 2017. The Company has signed agreements to provide its OnTrak solution to several health plans, including some of the largest in the United States (http://catasys.com/clients.html).
"This is an exciting opportunity to expand and leverage our existing operations in several states and significantly increase the number of eligible members for our OnTrak solution. This represents the first multi-state agreement which will use our analytic models for our expanded product offering covering high-cost members suffering from anxiety, depression or substance use disorders. We are very pleased with the reception our advanced proprietary solutions are receiving in the market," stated Rick Anderson, President and COO of Catasys.
"This particular health plan has an exceptional track record of innovation and providing care to its members. We are excited to partner with them and look forward to demonstrating the value of our solution," concluded Mr. Anderson.
Investor Call
The Company will hold a conference call with the investment community today, February 2, 2017 at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time. The dial-in numbers for the conference call are 1-888-427-9376 (Toll Free), 1-719-457-2639 (International). Please ask the operator to join you into the "Catasys Investor Call" or provide the conference ID number: 1474347.
A live webcast of the conference call will be available online which can be accessed on the Investor Relations section of the Catasys website: http://catasys.com/presentations.html. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast.
For interested individuals unable to join the conference call, a replay of the webcast will be available at http://catasys.com/presentations.html for 30 days following the call. Also, a dial-in replay of the call will be available through February 16, 2017, at +1-844-512-2921 (U.S. Toll Free) or 1-412-317-6671 (International). Participants must use the following code to access the dial-in replay of the call: 1474347.
About Catasys, Inc.
Catasys, Inc. provides big data based analytics and predictive modeling driven behavioral healthcare services to health plans and their members through its OnTrak solution. Catasys' OnTrak solution--contracted with a growing number of national and regional health plans--is designed to improve member health and, at the same time, lower costs to the insurer for underserved populations where behavioral health conditions cause or exacerbate co-existing medical conditions. The solution utilizes proprietary analytics and proprietary enrollment, engagement and behavioral modification capabilities to assist members who otherwise do not seek care through a patient-centric treatment that integrates evidence-based medical and psychosocial interventions along with care coaching in a 52-week outpatient treatment solution.
OnTrak is currently improving member health and, at the same time, is demonstrating reduced inpatient and emergency room utilization, driving a more than 50 percent reduction in total health insurers' costs for enrolled members. OnTrak is currently available to members of several leading health plans in Florida, Georgia, Illinois, Kansas, Kentucky, Louisiana, Massachusetts, Missouri, North Carolina, New Jersey, Oklahoma, Pennsylvania, South Carolina, Tennessee, Texas, Virginia, West Virginia and Wisconsin. For further information, please visit catasys.com.
Once we get through $1.55 we should get to $2
Here we go, breaking out again
$2 coming soon
and here's the move up
plus another great quarter of triple digit growth
Once the numbers start to get bigger this will be $5 quickly
setting up for another move higher
another big up day on huge volume......something is brewing here
More news today. Up big on huge volume
7.5M covered lives should translate into $30M in revenue 2017
Pretty good numbers. Percentage growth is great off a small base. They need to get the covered lives over 10M, then they'll do $40M-$50M in revenue
Nah bottom is in
Any information regarding CATS, that could lead me to a why or why not invest? My very basic information turned this up as a possible pick.
Ready to reload.
Ka-Ching$.
$CATS DD Notes ~ http://www.ddnotesmaker.com/CATS
bullish
$CATS recent news/filings
## source: finance.yahoo.com
Tue, 30 Sep 2014 12:41:26 GMT ~ CATASYS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities,
read full: http://biz.yahoo.com/e/140930/cats8-k.html
*********************************************************
Fri, 22 Aug 2014 17:04:10 GMT ~ CATASYS, INC. Financials
read full: http://finance.yahoo.com/q/is?s=cats
*********************************************************
Fri, 15 Aug 2014 13:05:27 GMT ~ CATASYS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
read full: http://biz.yahoo.com/e/140815/cats8-k.html
*********************************************************
Fri, 15 Aug 2014 13:00:00 GMT ~ Catasys Reports Rapid Growth in Second Quarter 2014 Results
[PR Newswire] - LOS ANGELES, Aug. 15, 2014 /PRNewswire/ -- Catasys, Inc. (OTCBB: CATS), provider of proprietary health management services to health insurers and employers, today announced its financial results for the ...
read full: http://finance.yahoo.com/news/catasys-reports-rapid-growth-second-130000726.html
*********************************************************
Thu, 14 Aug 2014 20:51:20 GMT ~ CATASYS, INC. Files SEC form 10-Q, Quarterly Report
read full: http://biz.yahoo.com/e/140814/cats10-q.html
*********************************************************
$CATS charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$CATS company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/CATS/company-info
Ticker: $CATS
OTC Market Place: OTCQB
CIK code: 0001136174
Company name: Catasys Inc.
Company website: http://www.catasyshealth.com
Incorporated In: DE, USA
$CATS share structure
## source: otcmarkets.com
Market Value: $49,306,438 a/o Oct 20, 2014
Shares Outstanding: 23,479,256 a/o Aug 13, 2014
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.001
$CATS extra dd links
Company name: Catasys Inc.
Company website: http://www.catasyshealth.com
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/CATS/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/CATS/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=CATS+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=CATS+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=CATS+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/CATS/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/CATS/news - http://finance.yahoo.com/q/h?s=CATS+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/CATS/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/CATS/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/CATS/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/CATS/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/CATS/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/CATS/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/CATS/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/CATS/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=CATS+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/CATS
DTCC (dtcc.com): http://search2.dtcc.com/?q=Catasys+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Catasys+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Catasys+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.catasyshealth.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.catasyshealth.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.catasyshealth.com
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/CATS/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/CATS
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/CATS/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/CATS/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/CATS/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001136174&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/CATS/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/CATS/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/CATS/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/CATS/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=CATS&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=CATS
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/CATS/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=CATS+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=CATS+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=CATS
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=CATS
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=CATS+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/CATS/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=CATS+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/CATS.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=CATS
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/CATS/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/CATS/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/CATS/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/CATS/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/CATS
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/CATS
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/CATS:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=CATS
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=CATS
$CATS DD Notes ~ http://www.ddnotesmaker.com/CATS
Catasys Inc. [$CATS] due diligence
bullish
$CATS
DD Notes ~ http://www.ddnotesmaker.com/CATS
##### recent news/filings ~ source: finance.yahoo.com
Wed, 25 Jun 2014 20:45:09 GMT ~ CATASYS, INC. Files SEC form 8-K/A, Change in Directors or Principal Officers
read full: http://biz.yahoo.com/e/140625/cats8-k_a.html
*********************************************************
Fri, 30 May 2014 15:58:00 GMT ~ Stocks: Insiders Buy at Dick's Sporting Goods and Cache
read full: http://www.minyanville.com/trading-and-investing/stocks/articles/Insiders-Buy-at-Dick2527s-Sporting-Goods/5/30/2014/id/55151?camp=syndication&medium=portals&from=yahoo
*********************************************************
Fri, 30 May 2014 10:03:25 GMT ~ CATASYS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities,
read full: http://biz.yahoo.com/e/140530/cats8-k.html
*********************************************************
Sat, 24 May 2014 17:04:11 GMT ~ CATASYS, INC. Financials
read full: http://finance.yahoo.com/q/is?s=cats
*********************************************************
Fri, 16 May 2014 13:07:49 GMT ~ CATASYS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
read full: http://biz.yahoo.com/e/140516/cats8-k.html
*********************************************************
##### chart ~ source: stockcharts.com
##### chart ~ source: eoddata.com
##### company info ~ source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/CATS/company-info
Ticker: $CATS
OTC Market Place: OTCQB
CIK code: 0001136174
Company name: Catasys Inc.
Company website: http://www.catasyshealth.com
Incorporated In: DE, USA
##### extra dd links
Edgar filings: http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001136174&owner=exclude&count=40
Latest filings: http://www.otcmarkets.com/stock/CATS/filings
Latest financials: http://www.otcmarkets.com/stock/CATS/financials
Latest news: http://www.otcmarkets.com/stock/CATS/news - http://finance.yahoo.com/q/h?s=CATS+Headlines
Major holdings: http://data.cnbc.com/quotes/CATS/tab/8.1
Insider transactions (1): http://finance.yahoo.com/q/it?s=CATS+Insider+Transactions
Insider transactions (2): http://www.secform4.com/insider-trading/CATS.htm
Insider transactions (3): http://www.insidercow.com/history/company.jsp?company=CATS
RegSho: http://www.regsho.com/tools/symbol_stats.php?sym=CATS&search=search
DTCC: http://search2.dtcc.com/?q=Catasys+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information: http://www.spoke.com/search?utf8=%E2%9C%93&q=Catasys+Inc.
Corporation WIKI: http://www.corporationwiki.com/search/results?term=Catasys+Inc.&x=0&y=0
WHOIS: http://whois.domaintools.com/http://www.catasyshealth.com
Alexa: http://www.alexa.com/siteinfo/http://www.catasyshealth.com#
Corporate website internet archive: http://web.archive.org/web/*/http://www.catasyshealth.com
Short Sales: http://www.otcmarkets.com/stock/CATS/short-sales
Insider Disclosure: http://www.otcmarkets.com/stock/CATS/insider-transactions
Research Reports: http://www.otcmarkets.com/stock/CATS/research
Historical Prices: http://finance.yahoo.com/q/hp?s=CATS+Historical+Prices
Basic Tech. Analysis: http://finance.yahoo.com/q/ta?s=CATS+Basic+Tech.+Analysis
Company Profile: http://finance.yahoo.com/q/pr?s=CATS+Profile
Key Statistics: http://finance.yahoo.com/q/ks?s=CATS+Key+Statistics
Industry: http://finance.yahoo.com/q/in?s=CATS+Industry
Insider Roster: http://finance.yahoo.com/q/ir?s=CATS+Insider+Roster
Income Statement: http://finance.yahoo.com/q/is?s=CATS
Balance Sheet: http://finance.yahoo.com/q/bs?s=CATS
Cash Flow: http://finance.yahoo.com/q/cf?s=CATS+Cash+Flow&annual
Market Watch: http://www.marketwatch.com/investing/stock/CATS
Bloomberg: http://www.bloomberg.com/quote/CATS:US
Morningstar: http://quotes.morningstar.com/stock/s?t=CATS
Bussinessweek: http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=CATS
Barchart: http://www.barchart.com/quotes/stocks/CATS
OTC Short Report: http://otcshortreport.com/index.php?index=CATS
Investopedia: http://www.investopedia.com/markets/stocks/CATS/?wa=0
http://www.pennystocktweets.com/stocks/profile/CATS
##### last known share structure ~ source: otcmarkets.com
Market Value: $42,420,744 a/o Jun 30, 2014
Shares Outstanding: 20,693,046 a/o May 14, 2014
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.001
##### business description ~ source: otcmarkets.com
DD Notes ~ http://www.ddnotesmaker.com/CATS
tnpc
Is it finally time for this CAT to pounce? I have been in the stock for a long time. It has been painful. But Crede Capital continues to invest in every round of financing that the company has done. Crede is Terren Peizer's investment vehicle. Peizer is also Chairman of CATS. So if you connect the dots here you can see that Peizer really believes that this company has a future. He is putting his own money at risk. The valuation for the company is cheap. Hundreds of millions of dollars have already been invested. I have not run this through my Insider Screen yet, but generally there are very few corporate executives of small companies that have invested $10 million in the business. I take this as a bullish sign. Also, looked at a number of Crede's portfolio companies and it looks like they have done really well so Peizer must know what he is doing.
Crede Capital and Terren Peizer continue to invest in every round of financing that the company has done. Crede is Terren Peizer's investment vehicle. Peizer is also Chairman of CATS. So if you connect the dots here you can see that Peizer really believes that this company has a future. He is putting his own money at risk. The valuation for the company is cheap. Hundreds of millions of dollars have already been invested. I have not run this through my Insider Screen yet, but generally there are very few corporate executives of small companies that have invested $10 million in the business. I take this as a bullish sign. Also, looked at a number of Crede's portfolio companies and it looks like they have done really well so Peizer must know what he is doing.
Don't be surprise if you see double digit
Double split, insider buying...what's the deal with this company?
CATS one for 10 reverse split:
http://www.otcbb.com/asp/dailylist_detail.asp?d=05/06/2013&mkt_ctg=OTCBB
CATS .115 178k vs 1.4k_vol10dayavg 10day alert, low float
update pending on court case around Apr 26th per 10K
setting up
Nice hit ~50k
looking for .19 .20
Reg SHO Threshold List: CATS
http://www.nasdaqtrader.com/trader.aspx?id=RegSHOThreshold
SS
Market Value1 $8,776,929 a/o Nov 02, 2012
Shares Outstanding 55,904,008 a/o Aug 13, 2012
insider buys
EC Transaction Summary — Last 6 Months
Buy/Sell
Buys
2
Sells
0
Total
2
Shares
Bought
16,460,000
Sold
0
Gross
16,460,000
Net
16,460,000
SEC Transactions Last 2 Years
Trans Date
Filer
Ownership
Type
Price
Shares
Sept 13, 2012 PEIZER TERREN S
Officer indirect Buy 0.10 9,810,000
Sept 13, 2012 SMITH DAVID E
Beneficial Owner (10%) direct Acquisition (Non Open Market) 0.10 6,650,000
Apr 18, 2012 SMITH DAVID E
Beneficial Owner (10%) direct Acquisition (Non Open Market) 0.16 8,312,500
Apr 17, 2012 PEIZER TERREN S
Officer indirect Buy NA 10,965,050
Followers
|
22
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
438
|
Created
|
12/09/07
|
Type
|
Free
|
Moderators |
Hythiam, Inc. provides through its Catasys® subsidiary, specialized behavioral health management services to health plans, employers and unions through a network of licensed and company managed health care providers. The Catasys Substance Dependence Program was designed to address substance dependence as a chronic disease. The program seeks to lower costs and improve member health through the delivery of integrated medical and psychosocial interventions in combination with long term care coaching, including the proprietary Prometa® Treatment Program for alcoholism and stimulant dependence. The Prometa Treatment Program, which integrates behavioral, nutritional, and medical components, is also available on a private-pay basis through licensed treatment providers.
Providing specialized behavioral health management services to health plans, employers and unions through a network of licensed and company managed health care providers.
For more info CatasysHealth.com
Hythiam Leadership Team | ![]() | |||||||||||||||||||||||
Terren S. Peizer
Terren S. Peizer is the founder of our company and has served as our chief executive officer and chairman of our Board of Directors since our inception in February 2003. He has served as Managing Director of Socius Capital Partners, LLC, since September 2009. Mr. Peizer has served on the board of Xcorporeal, Inc. since August 2007 and was executive chairman until October 2008. Mr. Peizer also served as chief executive officer of Clearant, Inc., a company which he founded in April 1999 to develop and commercialize a universal pathogen inactivation technology, until October 2003. He served as chairman of its board of directors from April 1999 to October 2004 and as a director until February 2005. In addition, from June 1999 through May 2003 he was a director, and from June 1999 through December 2000 he was chairman of the board, of supercomputer designer and builder Cray Inc., a NASDAQ Global Market company. Mr. Peizer has been the largest beneficial stockholder and has held various senior executive positions with several technology and biotech companies. He has assisted companies by assembling management teams, boards of directors and scientific advisory boards, formulating business and financial strategies, and investor relations. Mr. Peizer has a background in venture capital, investing, mergers and acquisitions, corporate finance, and previously held senior executive positions with the investment banking firms Goldman Sachs, First Boston and Drexel Burnham Lambert. He received his B.S.E. in Finance from The Wharton School of Finance and Commerce. Rick A. Anderson
Richard A. Anderson has more than fifteen years of experience in business development, strategic planning and financial management. He has served as a director since July 2003 and an officer since April 2005. He was the chief financial officer of Clearant, Inc. from November 1999 until March 2005, and served as a director from November 1999 to March 2006. Mr. Anderson was previously a director and founding member of PriceWaterhouseCoopers LLP’s, Los Angeles office transaction support group, where he was involved in operational and financial due diligence, valuations and structuring for high technology companies. He received a B.A. in Business Economics from University of California, Santa Barbara. Peter Donato
Peter Donato has nearly 20 years of progressive financial management experience in large, publicly traded companies as well as small, entrepreneurial companies. He began his career in public accounting with Ernst & Young, and most recently served as CFO of Iris International, a NASDAQ traded medical diagnostics equipment manufacturer, and CFO of Gamma Medica-Ideas, an early stage medical imaging company. He is credited for establishing a strong and timely reporting structure, improved control environment, recruiting and retaining strong accounting, finance and IT teams, as well as developing and maintaining strong relationships with external stakeholders including: investors, coverage analysts, bankers, insurance brokers and auditors. He has held positions with increasing responsibilities at General Motors, Honda, Scotts-Miracle Gro, and Accellent. Mr. Donato graduated from The Ohio State University with a BS in Business Administration and earned an MBA from the University of Akron. Gary Ingenito, MD, PhD
Dr. Ingenito is responsible for preclinical and clinical scientific research and development. He is a member of the senior executive management team, providing strategic direction for future clinical trials, clinical product development, creation of expanded patient treatment algorithms, data analysis and reporting. Dr. Ingenito previously held executive positions at Angiotech, SFBC International, Otsuka Pharmaceuticals, Corning-Besselaar, and Novartis. A neurologist, Dr. Ingenito
Mr. McLane is responsible for the overall sales and marketing efforts of the company, encompassing customer acquisition, marketing strategy, market research, member outreach and account management. Prior to joining the company he led the marketing activities for Magellan Health Services and founded Optimized Benefits, Inc., a health benefits company that replaced the one-size-fits-all HMO, PPO and CDHP plans with “Life Stage” plans which address the different needs of employees at various stages of their lives. He also led strategy development and product development for CIGNA and ran consumer products businesses for Procter & Gamble, Campbell Soup and Nabisco. Mr. McLane earned a Bachelor of Science degree from The Wharton School of the University of Pennsylvania with majors in accounting and decision science, and a Masters of Business Administration from Cornell University with concentrations in management and organizational behavior.
Dr. Weinstein leads the clinical initiatives for the development of clinical products and provides medical leadership for the business development, marketing and site management departments. Dr. Weinstein also serves as the primary clinical liaison to licensees, physician groups, corporate affiliations, managed care organizations, insurers and external affairs. Prior to Catasys, Dr. Weinstein held positions at PacifiCare Behavioral Health/United Behavioral Health, Magellan Behavioral Health and the Chemical Dependence Unit at St. Elizabeth’s Hospital in Chicago. He has also worked in private practice providing individual and group diagnostic and psychotherapeutic services, as well as family therapy. Dr. Weinstein received his M.D. from the Ross University School of Medicine, and completed his internship and residency in psychiatry at Michael Reese Hospital and Medical Center in Chicago. |
Hythiam Board of Directors | ![]() | |
Terren S. Peizer Chairman and Chief Executive Officer Terren S. Peizer is the founder of our company and has served as our chief executive officer and chairman of our Board of Directors since our inception in February 2003. He has served as Managing Director of Socius Capital Partners, LLC, since September 2009. Mr. Peizer has served on the board of Xcorporeal, Inc. since August 2007 and was executive chairman until October 2008. Mr. Peizer also served as chief executive officer of Clearant, Inc., a company which he founded in April 1999 to develop and commercialize a universal pathogen inactivation technology, until October 2003. He served as chairman of its board of directors from April 1999 to October 2004 and as a director until February 2005. In addition, from June 1999 through May 2003 he was a director, and from June 1999 through December 2000 he was chairman of the board, of supercomputer designer and builder Cray Inc., a NASDAQ Global Market company. Mr. Peizer has been the largest beneficial stockholder and has held various senior executive positions with several technology and biotech companies. He has assisted companies by assembling management teams, boards of directors and scientific advisory boards, formulating business and financial strategies, and investor relations. Mr. Peizer has a background in venture capital, investing, mergers and acquisitions, corporate finance, and previously held senior executive positions with the investment banking firms Goldman Sachs, First Boston and Drexel Burnham Lambert. He received his B.S.E. in Finance from The Wharton School of Finance and Commerce. Rick A. Anderson President and Chief Operating Officer Rick A. Anderson, has more than fifteen years of experience in business development, strategic planning and financial management. He has served as a director since July 2003 and an officer since April 2005. He was the chief financial officer of Clearant, Inc. from November 1999 until March 2005, and served as a director from November 1999 to March 2006. Mr. Anderson was previously a director and founding member of PriceWaterhouseCoopers LLP’s, Los Angeles office transaction support group, where he was involved in operational and financial due diligence, valuations and structuring for high technology companies. He received a B.A. in Business Economics from University of California, Santa Barbara. ![]() Andrea Grubb Barthwell, M.D., F.A.S.A.M. Andrea Grubb Barthwell, M.D., F.A.S.A.M., is the founder and Chief Executive Officer of the global health care and policy-consulting firm EMGlobal LLC and Director at Two Dreams Outer Banks Treatment Center. President George W. Bush nominated Dr. Barthwell in December 2001 to serve as Deputy Director for Demand Reduction in the Office of National Drug Control Policy (ONDCP). The United States Senate confirmed her nomination on January 28, 2002. As a member of the President's sub-cabinet, Dr. Barthwell was a principal advisor in the Executive Office of the President (EOP) on policies aimed at reducing the demand for illicit drugs. Dr. Barthwell received a Bachelor of Arts degree in Psychology from Wesleyan University, where she serves on the Board of Trustees, and a Doctor of Medicine from the University of Michigan Medical School. Following post-graduate training at the University of Chicago and Northwestern University Medical Center, she began her practice in the Chicago area. Dr. Barthwell served as President of the Encounter Medical Group (EMG, an affiliate of EMGlobal), was a founding member of the Chicago Area AIDS Task Force, hosted a weekly local cable show on AIDS, and is a past president of the American Society of Addiction Medicine. Dr. Barthwell received the Betty Ford Award, given by the Association for Medical Education and Research in Substance Abuse and has been named by her peers as one of the "Best Doctors in America" in addiction medicine. Marc G. Cummins Marc G. Cummins is a managing partner of Prime Capital, LLC, a private investment firm focused on consumer companies. Prior to founding Prime Capital, Mr. Cummins was managing partner of Catterton Partners, a private equity investor in consumer products and service companies with more than $1 billion of assets under management. Prior to joining Catterton in 1998, Mr. Cummins spent fourteen years at Donaldson, Lufkin & Jenrette Securities Corporation where he was managing director of the Consumer Products and Specialty Distribution Group, and was also involved in leveraged buyouts, private equity and high yield financings. Mr. Cummins received a B.A. in Economics, magna cum laude, from Middlebury College, where he was honored as a Middlebury College Scholar and is a member of Phi Beta Kappa. He also received an M.B.A. in Finance with honors from The Wharton School at University of Pennsylvania. Jay A. Wolf Jay A. Wolf has served as a director since June 2008. He is the founder and principal of Wolf Capital LP an investment advisory firm he formed in October 2009 to focus on small cap public companies. From November 2003 until September 2009, Mr. Wolf was a partner at Trinad Capital LLC, an activist hedge fund focused on micro-cap public companies. During his work at Trinad, Mr. Wolf assisted distressed and early stage public companies through active board participation, the assembly of management teams and business and financial strategies. Prior to his work at Trinad, Mr. Wolf served as executive vice president of Corporate Development for Wolf Group Integrated Communications Ltd. Prior to that, Mr. Wolf worked at Canadian Corporate Funding, Ltd., a Toronto-based merchant bank as an analyst in the firm’s senior debt department and subsequently for Trillium Growth Capital, the firm’s venture capital fund. Mr. Wolf currently also sits on the boards of Xcorporeal, Inc. (XCR), Zoo Entertainment, Inc. (ZOOE) and NorthStar Systems, Inc. Mr. Wolf is also a member of the board of governors at Cedars-Sinai Hospital. He is a former director of Asianada, Inc., ProLink Holdings Corp., Mandalay Media, Inc., Atrinsic, Inc., Shells Seafood Restaurants, Inc., Optio Software, Inc., Xcorporeal Operations, Inc., Zane Acquisition I, Inc., Zane Acquisition II, Inc., Starvox Communications, Inc. and Noble Medical Technologies, Inc. Mr. Wolf received his B.A from Dalhousie University. Mr. Wolf was chief operating officer and chief financial officer of Starvox Communications, Inc. from March 2005 to March 2007. On March 26, 2008, StarVox Communications, Inc. filed a voluntary petition for liquidation under Chapter 7 of the United States Bankruptcy Code in the United States Bankruptcy Court for the Northern District of California, San Jose. Shells Seafood Restaurants, Inc., a company for which Mr. Wolf formerly served as a director, filed a voluntary petition for reorganization under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the Middle District of Florida, Tampa Division, on September 2, 2008. Mr. Wolf’s broad range of investment and operations experience, which includes senior and subordinated debt lending, private equity and venture capital investments, mergers and acquisitions advisory work and public equity investments, equip him with the qualifications and skills to serve on our Board of Directors. |
Form Type | Received | Period Ending | Size | Report |
---|---|---|---|---|
POS AM | Oct 1, 2010 | 49.2 KB | ![]() ![]() ![]() ![]() | |
POS AM | Oct 1, 2010 | 48.5 KB | ![]() ![]() ![]() ![]() | |
AW | Sept 28, 2010 | 12.6 KB | ![]() ![]() ![]() | |
AW | Sept 28, 2010 | 12.6 KB | ![]() ![]() ![]() | |
POS EX | Sept 21, 2010 | 48.6 KB | ![]() ![]() ![]() ![]() | |
POS EX | Sept 21, 2010 | 49.4 KB | ![]() ![]() ![]() ![]() | |
3 | Sept 3, 2010 | Aug 25, 2010 | 4.3 KB | ![]() ![]() ![]() ![]() |
8-K | Aug 27, 2010 | Aug 25, 2010 | 38.5 KB | ![]() ![]() ![]() ![]() |
10-Q | Aug 16, 2010 | Jun 30, 2010 | 1.2 MB | ![]() ![]() ![]() ![]() |
8-K | Jul 7, 2010 | Jul 7, 2010 | 18.8 KB | ![]() ![]() ![]() ![]() |
Shares Outstanding | 55,154,688 | a/o Apr 28, 2009 |
American Stock Transfer & Trust Company |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |